A case series of drotrecogin alfa (activated) in lung transplant recipients.
Severe sepsis in lung transplant recipients is a challenging problem and carries a high mortality. Recombinant human activated protein C (drotrecogin alfa [activated]) has been approved for use in patients with severe sepsis. Its use has been shown to be safe and impart a survival advantage. However, the safety of drotrecogin alfa activated has not been evaluated in lung transplant recipients. We report for the first time on the use of drotrecogin alfa activated in six lung transplant recipients. Clinical trials are warranted to further evaluate the use of drotrecogin alfa activated in transplant recipients.
Daniels
Titus L
TL
Division of Infectious Diseases, Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA. titus.daniels@vanderbilt.edu
Dummer
J Stephen
JS
Bernard
Gordon R
GR
Milstone
Aaron P
AP
D000328:Adult; D005260:Female; D006801:Humans; D016040:Lung Transplantation; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated